DavidWOllilaMD

Breast, Melanoma, Surgical Oncology (Other than Breast)

James and Jesse Millis Distinguished Professor of Surgery, Co-Leader UNC Multidisciplinary Melanoma and Complex Skin Cancer Program, University of North Carolina at Chapel Hill School of Medicine

Join to view full profile

Dr. Ollila is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Ollila's full profile

Already have an account?

Office
170 Manning Drive
Chapel Hill, NC 27599
Phone+1 919-966-5221

Fax+1 919-966-8806

Education & Training

Saint John’s Cancer Institute/Providence Saint John’s Health CenterFellowship, Complex General Surgical Oncology, 1995 - 1998
OhioHealth/Riverside Methodist HospitalResidency, Surgery, 1990 - 1995
University of Cincinnati College of MedicineClass of 1990

Certifications & Licensure

CA State Medical License 1995 - Present
NC State Medical License 1998 - 2025
American Board of Surgery Surgery

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Fellow (FACS) American College of Surgeons

Clinical Trials

Molecular Marker Profiling of Axillary Lymph Nodes in Predicting Response in Patients With Locally Advanced or Metastatic Breast Cancer Who Are Undergoing Chemotherapy Followed By Surgery Start of enrollment: 2002 May 01
Completed
Phase 2
Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer Start of enrollment: 2012 Jul 01
Completed
Phase 2
Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma Start of enrollment: 2019 Dec 17
Recruiting
Phase 3
Roles: Principal Investigator, Contact

Publications & Presentations

PubMed

207 citations
Tumor-Infiltrating Lymphocyte Grade in Primary Melanomas Is Independently Associated With Melanoma-Specific Survival in the Population-Based Genes, Environment and Mel...
Nancy E. Thomas, Klaus J. Busam, Lynn From, Anne Kricker, Bruce K. Armstrong
Journal of Clinical Oncology. 2013-11-20
1508 citations
The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes
Lisa A. Carey, E. Claire Dees, Lynda R. Sawyer, Lisa Gatti, Dominic T. Moore
Clinical Cancer Research. 2007-04-15
26 citations
Patterns of Local-Regional Management Following Neoadjuvant Chemotherapy in Breast Cancer: Results From ACOSOG Z1071 (Alliance)
Bruce G. Haffty, Linda M. McCall, Karla V. Ballman, Sarah A. McLaughlin, Reshma Jagsi
International Journal of Radiation Oncology, Biology, Physics. 2016-03-01

Journal Articles

The Changing Paradigms for Breast Cancer Surgery: Performing Fewer and Less-Invasive Operations
David R Brenin, E Shelley Hwang, Katharine Yao, David W Ollila, Henry M Kuerer, Annals of Surgical Oncology

Press Mentions

2019 Oncology Excellence Awards Celebrate Compassionate Nurses and StaffOctober 8th, 2019
Melanoma Symposium to Include Talks on Treatment, NutritionMarch 11th, 2019
How Effective Is Talimogene Laherparepvec Injection in Metastatic Melanoma?February 1st, 2019

Grant Support

Immunotherapy With A Polyvalent Melanoma Vaccine PLUS BCG In Stage IVNational Center For Research Resources2004–2006
Active Immunotherapy With A Polyvalent Melanoma Vaccine In Stage IIINational Center For Research Resources2004–2006
Immunotherapy W/ Melanoma Vaccine PLUS BCG In MelanomaNational Center For Research Resources2000
Active Immunotherapy W/ BCG &Melanoma Vaccine, CancervaNational Center For Research Resources2000